Results

1–6 of 6 results for therapeutics

PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2025
Intravitreal Therapeutics Utilization in 2023
Anton M Kolomeyer, MD, PhD
Annual Meeting Talks
2024
Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option
Mohsin H. Ali, MD
Updates from the Field
2025
Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2021
New Therapeutics for Uveitis and Best Uveitis Cases
Sunil Srivastava, MD
Updates from the Field
2017
Future DME Therapeutics
Updates from the Field
2017